Fennec Pharmaceuticals (FENC) vs Opus Genetics (IRD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Opus Genetics (IRD) has outperformed Fennec Pharmaceuticals (FENC) over the past year, gaining 117.2% versus a gain of 9.3%. Over five years, FENC leads with a +12.7% price change compared with +2.8% for IRD. Fennec Pharmaceuticals is the larger company by market cap ($363.5 million vs $357.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FENC | IRD |
|---|---|---|
| Share price | $10.37 | $4.30 |
| Market cap | $363.47M | $357.74M |
| 1-day change | +0.05% | -2.49% |
| YTD return | +34.55% | +119.40% |
| 1-year return | +9.28% | +117.24% |
| 5-year return | +12.73% | +2.80% |
| Forward P/E | 10.93 | — |
| EPS (TTM) | $-0.12 | $-1.27 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $13.25 | $7.07 |
| 52-week low | $5.65 | $1.70 |
| Distance from 52-week high | -21.77% | -39.18% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +70.48% | +211.86% |
| Average volume | 193.31K | 2.37M |
| Shares outstanding | 35.07M | 83.20M |
| Employees | 35 | 27 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IRD has outperformed FENC by 108.0 percentage points over the past year.
About Fennec Pharmaceuticals
FENC stock →Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 35 employees
About Opus Genetics
IRD stock →Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 27 employees
FENC vs IRD FAQ
Which is bigger, Fennec Pharmaceuticals or Opus Genetics?
Fennec Pharmaceuticals (FENC) is larger, with a market capitalization of $363.47M compared with $357.74M for Opus Genetics (IRD).
Which stock has performed better over the past year, FENC or IRD?
IRD returned +117.24% over the past 12 months, compared with +9.28% for FENC (price return, excluding dividends). Past performance does not predict future results.
Are Fennec Pharmaceuticals and Opus Genetics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Fennec Pharmaceuticals and Biotechnology: Pharmaceutical Preparations for Opus Genetics.